While the BCL2 inhibitor venetoclax has shown modest single‐agent activity in aggressive lymphomas, including diffuse large B‐cell lymphoma (DLBCL) and peripheral T‐cell lymphoma (PTCL), durable remissions are rarely observed.7, 8. Here, BCL2 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.